Drug intelligence / Profile preview

KLOT-1123

Development stage: Preclinical
Lead developer: EPOK Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

KLOT-1123 is a novel monoclonal antibody developed by EPOK Therapeutics for the treatment of hypophosphatemic disorders and chronic kidney disease (CKD) associated with high fibroblast growth factor 23 (FGF23) bioactivity. It acts as an antagonist to FGF23, a hormone involved in phosphate metabolism, and is being investigated for its potential to treat conditions where excessive FGF23 activity leads to metabolic disturbances such as hypophosphatemia and CKD. The drug is currently in preclinical development[1][2][6].

Other names: KLOT-1123AKLOT1123AKLOT 1123A

Targets

FGF23 (Fibroblast growth factor 23)

Beyond the preview

Go deeper on KLOT-1123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KLOT-1123.

Explore the full profile